All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.
The mpn Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mpn Hub cannot guarantee the accuracy of translated content. The mpn and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mpn content recommended for you
Impact of a reduced starting dose of ruxolitinib on survival in patients with MF
|
A retrospective analysis of a prospective observational cohort from AIFA Monitoring Registries assessed the association between the starting dose of ruxolitinib, an oral JAK1/2 inhibitor, and long-term outcomes in 3,494 patients with MF.1 Results from this analysis were published in the British Journal of Haematology by Breccia et al.1 |
| Key learnings |
| Patients initiating ruxolitinib at reduced doses (n = 2,337) were generally older, with larger splenomegaly, higher IPSS risk, and worse ECOG scores. |
| After balancing for baseline characteristics, initiating ruxolitinib at a reduced dose was associated with a shorter median OS (52.6 months vs. 78.2 months; HR, 1.444; 95% CI, 1.296–1.609; p <0.001) compared with starting at the full dose. |
| Subgroup analysis indicated that the reduced starting dose affected OS in patients with intermediate-2 (HR, 1.491; 95% CI, 1.294–1.718; p <0.001) and high (HR, 1.398; 95% CI, 1.176–1.66; p <0.001) IPSS risk. |
| These findings show that, regardless of the baseline characteristics, a reduced starting dose of ruxolitinib was associated with worse survival outcomes in patients with intermediate-2 and high-risk MF. |
Abbreviations: AIFA, Agenzia Italiana del Farmaco; CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; HR, hazard ratio; IPSS, International Prognostic Scoring System; JAK, Janus kinase; MF, myelofibrosis; OS, overall survival.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
